 | • レポートコード：MRCLP3DB6874 • 出版社/出版日：LP Information / 2023年12月 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（納期：2-3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥541,680 (USD3,660) | ▷ お問い合わせ |
| Corporate User | ￥1,083,360 (USD7,320) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| LPインフォメーション社の最新調査レポート「前立腺がんPARP阻害剤の世界市場」は、過去の販売実績から2022年の世界の前立腺がんPARP阻害剤の総販売量を検討し、2023年から2029年の予測される前立腺がんPARP阻害剤の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の前立腺がんPARP阻害剤の市場規模を掲載し、XXX百万米ドル規模の世界の前立腺がんPARP阻害剤市場の詳細な分析を提供します。本インサイトレポートは、世界の前立腺がんPARP阻害剤業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。 また、本資料では、加速する世界の前立腺がんPARP阻害剤市場における各社の独自のポジションをより深く理解するために、前立腺がんPARP阻害剤製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。 世界の前立腺がんPARP阻害剤市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。前立腺がんPARP阻害剤の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。前立腺がんPARP阻害剤の中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。前立腺がんPARP阻害剤の欧州市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。 前立腺がんPARP阻害剤の世界主要メーカーとしては、AstraZeneca、 Merck & Co., Inc、 GSK、 Pfizer、 Johnson & Johnson、 Takeda Pharmaceutical Company Limited、 BeiGene, Inc、 Jiangsu Hengrui Pharmaceuticals Co., Ltdなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。 本調査資料では、製品タイプ、用途、主要メーカー、主要地域、国別の前立腺がんPARP阻害剤市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。 【市場細分化】 本調査では前立腺がんPARP阻害剤市場をセグメンテーションし、種類別 (リムパーザ、ゼジュラ、タルゼンナ、フルゾパリブ、パミパリ、他)、用途別 (病院、専門診療所、その他)、および地域別 (アジア太平洋、南北アメリカ、欧州、および中東・アフリカ) の市場規模を予測しています。 ・種類別区分：リムパーザ、ゼジュラ、タルゼンナ、フルゾパリブ、パミパリ、他 ・用途別区分：病院、専門診療所、その他 ・地域別区分 南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル） アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア） 欧州（ドイツ、フランス、イギリス、イタリア、ロシア） 中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国） 【本レポートで扱う主な質問】 ・世界の前立腺がんPARP阻害剤市場の10年間の市場状況・展望は？ ・世界および地域別に見た前立腺がんPARP阻害剤市場成長の要因は何か？ ・前立腺がんPARP阻害剤の市場機会はエンドマーケットの規模によってどのように変化するのか？ ・前立腺がんPARP阻害剤のタイプ別、用途別の内訳は？ ・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？ ********* 目次 ********* レポートの範囲 ・市場の紹介 ・分析対象期間 ・調査の目的 ・調査手法 ・調査プロセスおよびデータソース ・経済指標 ・通貨 エグゼクティブサマリー ・世界市場の概要：前立腺がんPARP阻害剤の年間販売量2018-2029、地域別現状・将来分析 ・前立腺がんPARP阻害剤の種類別セグメント：リムパーザ、ゼジュラ、タルゼンナ、フルゾパリブ、パミパリ、他 ・前立腺がんPARP阻害剤の種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格 ・前立腺がんPARP阻害剤の用途別セグメント：病院、専門診療所、その他 ・前立腺がんPARP阻害剤の用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格 企業別世界の前立腺がんPARP阻害剤市場 ・企業別のグローバル前立腺がんPARP阻害剤市場データ：2018-2023年の年間販売量、市場シェア ・企業別の前立腺がんPARP阻害剤の年間売上：2018-2023年の売上、市場シェア ・企業別の前立腺がんPARP阻害剤販売価格 ・主要企業の前立腺がんPARP阻害剤生産地域、販売地域、製品タイプ ・市場集中度分析 ・新製品および潜在的な参加者 ・合併と買収、拡大 前立腺がんPARP阻害剤の地域別レビュー ・地域別の前立腺がんPARP阻害剤市場規模2018-2023：年間販売量、売上 ・主要国別の前立腺がんPARP阻害剤市場規模2018-2023：年間販売量、売上 ・南北アメリカの前立腺がんPARP阻害剤販売の成長 ・アジア太平洋の前立腺がんPARP阻害剤販売の成長 ・欧州の前立腺がんPARP阻害剤販売の成長 ・中東・アフリカの前立腺がんPARP阻害剤販売の成長 南北アメリカ市場 ・南北アメリカの国別の前立腺がんPARP阻害剤販売量、売上（2018-2023） ・南北アメリカの前立腺がんPARP阻害剤の種類別販売量 ・南北アメリカの前立腺がんPARP阻害剤の用途別販売量 ・アメリカ市場 ・カナダ市場 ・メキシコ市場 ・ブラジル市場 アジア太平洋市場 ・アジア太平洋の国別の前立腺がんPARP阻害剤販売量、売上（2018-2023） ・アジア太平洋の前立腺がんPARP阻害剤の種類別販売量 ・アジア太平洋の前立腺がんPARP阻害剤の用途別販売量 ・中国市場 ・日本市場 ・韓国市場 ・東南アジア市場 ・インド市場 ・オーストラリア市場 ・台湾市場 欧州市場 ・欧州の国別の前立腺がんPARP阻害剤販売量、売上（2018-2023） ・欧州の前立腺がんPARP阻害剤の種類別販売量 ・欧州の前立腺がんPARP阻害剤の用途別販売量 ・ドイツ市場 ・フランス市場 ・イギリス市場 ・イタリア市場 ・ロシア市場 中東・アフリカ市場 ・中東・アフリカの国別の前立腺がんPARP阻害剤販売量、売上（2018-2023） ・中東・アフリカの前立腺がんPARP阻害剤の種類別販売量 ・中東・アフリカの前立腺がんPARP阻害剤の用途別販売量 ・エジプト市場 ・南アフリカ市場 ・イスラエル市場 ・トルコ市場 ・GCC諸国市場 市場の成長要因、課題、動向 ・市場の成長要因および成長機会分析 ・市場の課題およびリスク ・市場動向 製造コスト構造分析 ・原材料とサプライヤー ・前立腺がんPARP阻害剤の製造コスト構造分析 ・前立腺がんPARP阻害剤の製造プロセス分析 ・前立腺がんPARP阻害剤の産業チェーン構造 マーケティング、販売業者および顧客 ・販売チャンネル：直接販売チャンネル、間接販売チャンネル ・前立腺がんPARP阻害剤の主要なグローバル販売業者 ・前立腺がんPARP阻害剤の主要なグローバル顧客 地域別の前立腺がんPARP阻害剤市場予測レビュー ・地域別の前立腺がんPARP阻害剤市場規模予測（2024-2029） ・南北アメリカの国別予測 ・アジア太平洋の国別予測 ・欧州の国別予測 ・前立腺がんPARP阻害剤の種類別市場規模予測 ・前立腺がんPARP阻害剤の用途別市場規模予測 主要企業分析 AstraZeneca、 Merck & Co., Inc、 GSK、 Pfizer、 Johnson & Johnson、 Takeda Pharmaceutical Company Limited、 BeiGene, Inc、 Jiangsu Hengrui Pharmaceuticals Co., Ltd ・企業情報 ・前立腺がんPARP阻害剤製品 ・前立腺がんPARP阻害剤販売量、売上、価格、粗利益（2018-2023） ・主要ビジネス概要 ・最新動向 調査結果および結論 |
The global Prostate Cancer PARP Inhibitor Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Prostate Cancer PARP Inhibitor Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Prostate Cancer PARP Inhibitor Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Prostate Cancer PARP Inhibitor Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Prostate Cancer PARP Inhibitor Drugs players cover AstraZeneca, Merck & Co., Inc, GSK, Pfizer, Johnson & Johnson, Takeda Pharmaceutical Company Limited, BeiGene, Inc and Jiangsu Hengrui Pharmaceuticals Co., Ltd, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Poly ADP-ribose polymerase (PARP) is a DNA repair enzyme involved in the single-strand repair process of DNA. PARP inhibitors (PARPi) inhibit PARP activity through two mechanisms: direct inhibition of PARP function and PARP trapping, resulting in the stalling and collapse of replication forks, resulting in fatal double-strand breaks. Normal cells can repair double-strand breaks in time and correctly through homologous recombination repair (HRR); however, in tumor cells carrying HRR gene mutations, due to the impairment or loss of HRR function, the accumulated double-strand breaks will not be repaired in time and correctly, resulting in The tumor cell genome is unstable and eventually induces tumor cell death.
LPI (LP Information)’ newest research report, the “Prostate Cancer PARP Inhibitor Drugs Industry Forecast” looks at past sales and reviews total world Prostate Cancer PARP Inhibitor Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Prostate Cancer PARP Inhibitor Drugs sales for 2023 through 2029. With Prostate Cancer PARP Inhibitor Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Prostate Cancer PARP Inhibitor Drugs industry.
This Insight Report provides a comprehensive analysis of the global Prostate Cancer PARP Inhibitor Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Prostate Cancer PARP Inhibitor Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Prostate Cancer PARP Inhibitor Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Prostate Cancer PARP Inhibitor Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Prostate Cancer PARP Inhibitor Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Prostate Cancer PARP Inhibitor Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Lynparza
Zejula
Talzenna
Fluzoparib
PamiPali
Other
Segmentation by application
Hospital
Specialty Clinic
other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
AstraZeneca
Merck & Co., Inc
GSK
Pfizer
Johnson & Johnson
Takeda Pharmaceutical Company Limited
BeiGene, Inc
Jiangsu Hengrui Pharmaceuticals Co., Ltd
Key Questions Addressed in this Report
What is the 10-year outlook for the global Prostate Cancer PARP Inhibitor Drugs market?
What factors are driving Prostate Cancer PARP Inhibitor Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Prostate Cancer PARP Inhibitor Drugs market opportunities vary by end market size?
How does Prostate Cancer PARP Inhibitor Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Prostate Cancer PARP Inhibitor Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Prostate Cancer PARP Inhibitor Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Prostate Cancer PARP Inhibitor Drugs by Country/Region, 2018, 2022 & 2029
2.2 Prostate Cancer PARP Inhibitor Drugs Segment by Type
2.2.1 Lynparza
2.2.2 Zejula
2.2.3 Talzenna
2.2.4 Fluzoparib
2.2.5 PamiPali
2.2.6 Other
2.3 Prostate Cancer PARP Inhibitor Drugs Sales by Type
2.3.1 Global Prostate Cancer PARP Inhibitor Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Prostate Cancer PARP Inhibitor Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Prostate Cancer PARP Inhibitor Drugs Sale Price by Type (2018-2023)
2.4 Prostate Cancer PARP Inhibitor Drugs Segment by Application
2.4.1 Hospital
2.4.2 Specialty Clinic
2.4.3 other
2.5 Prostate Cancer PARP Inhibitor Drugs Sales by Application
2.5.1 Global Prostate Cancer PARP Inhibitor Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Prostate Cancer PARP Inhibitor Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Prostate Cancer PARP Inhibitor Drugs Sale Price by Application (2018-2023)
3 Global Prostate Cancer PARP Inhibitor Drugs by Company
3.1 Global Prostate Cancer PARP Inhibitor Drugs Breakdown Data by Company
3.1.1 Global Prostate Cancer PARP Inhibitor Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Prostate Cancer PARP Inhibitor Drugs Sales Market Share by Company (2018-2023)
3.2 Global Prostate Cancer PARP Inhibitor Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Prostate Cancer PARP Inhibitor Drugs Revenue by Company (2018-2023)
3.2.2 Global Prostate Cancer PARP Inhibitor Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Prostate Cancer PARP Inhibitor Drugs Sale Price by Company
3.4 Key Manufacturers Prostate Cancer PARP Inhibitor Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Prostate Cancer PARP Inhibitor Drugs Product Location Distribution
3.4.2 Players Prostate Cancer PARP Inhibitor Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Prostate Cancer PARP Inhibitor Drugs by Geographic Region
4.1 World Historic Prostate Cancer PARP Inhibitor Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Prostate Cancer PARP Inhibitor Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Prostate Cancer PARP Inhibitor Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Prostate Cancer PARP Inhibitor Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Prostate Cancer PARP Inhibitor Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Prostate Cancer PARP Inhibitor Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Prostate Cancer PARP Inhibitor Drugs Sales Growth
4.4 APAC Prostate Cancer PARP Inhibitor Drugs Sales Growth
4.5 Europe Prostate Cancer PARP Inhibitor Drugs Sales Growth
4.6 Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Sales Growth
5 Americas
5.1 Americas Prostate Cancer PARP Inhibitor Drugs Sales by Country
5.1.1 Americas Prostate Cancer PARP Inhibitor Drugs Sales by Country (2018-2023)
5.1.2 Americas Prostate Cancer PARP Inhibitor Drugs Revenue by Country (2018-2023)
5.2 Americas Prostate Cancer PARP Inhibitor Drugs Sales by Type
5.3 Americas Prostate Cancer PARP Inhibitor Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Prostate Cancer PARP Inhibitor Drugs Sales by Region
6.1.1 APAC Prostate Cancer PARP Inhibitor Drugs Sales by Region (2018-2023)
6.1.2 APAC Prostate Cancer PARP Inhibitor Drugs Revenue by Region (2018-2023)
6.2 APAC Prostate Cancer PARP Inhibitor Drugs Sales by Type
6.3 APAC Prostate Cancer PARP Inhibitor Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Prostate Cancer PARP Inhibitor Drugs by Country
7.1.1 Europe Prostate Cancer PARP Inhibitor Drugs Sales by Country (2018-2023)
7.1.2 Europe Prostate Cancer PARP Inhibitor Drugs Revenue by Country (2018-2023)
7.2 Europe Prostate Cancer PARP Inhibitor Drugs Sales by Type
7.3 Europe Prostate Cancer PARP Inhibitor Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Prostate Cancer PARP Inhibitor Drugs by Country
8.1.1 Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Sales by Type
8.3 Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Prostate Cancer PARP Inhibitor Drugs
10.3 Manufacturing Process Analysis of Prostate Cancer PARP Inhibitor Drugs
10.4 Industry Chain Structure of Prostate Cancer PARP Inhibitor Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Prostate Cancer PARP Inhibitor Drugs Distributors
11.3 Prostate Cancer PARP Inhibitor Drugs Customer
12 World Forecast Review for Prostate Cancer PARP Inhibitor Drugs by Geographic Region
12.1 Global Prostate Cancer PARP Inhibitor Drugs Market Size Forecast by Region
12.1.1 Global Prostate Cancer PARP Inhibitor Drugs Forecast by Region (2024-2029)
12.1.2 Global Prostate Cancer PARP Inhibitor Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Prostate Cancer PARP Inhibitor Drugs Forecast by Type
12.7 Global Prostate Cancer PARP Inhibitor Drugs Forecast by Application
13 Key Players Analysis
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca Prostate Cancer PARP Inhibitor Drugs Product Portfolios and Specifications
13.1.3 AstraZeneca Prostate Cancer PARP Inhibitor Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 Merck & Co., Inc
13.2.1 Merck & Co., Inc Company Information
13.2.2 Merck & Co., Inc Prostate Cancer PARP Inhibitor Drugs Product Portfolios and Specifications
13.2.3 Merck & Co., Inc Prostate Cancer PARP Inhibitor Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Merck & Co., Inc Main Business Overview
13.2.5 Merck & Co., Inc Latest Developments
13.3 GSK
13.3.1 GSK Company Information
13.3.2 GSK Prostate Cancer PARP Inhibitor Drugs Product Portfolios and Specifications
13.3.3 GSK Prostate Cancer PARP Inhibitor Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 GSK Main Business Overview
13.3.5 GSK Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Prostate Cancer PARP Inhibitor Drugs Product Portfolios and Specifications
13.4.3 Pfizer Prostate Cancer PARP Inhibitor Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Johnson & Johnson
13.5.1 Johnson & Johnson Company Information
13.5.2 Johnson & Johnson Prostate Cancer PARP Inhibitor Drugs Product Portfolios and Specifications
13.5.3 Johnson & Johnson Prostate Cancer PARP Inhibitor Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Johnson & Johnson Main Business Overview
13.5.5 Johnson & Johnson Latest Developments
13.6 Takeda Pharmaceutical Company Limited
13.6.1 Takeda Pharmaceutical Company Limited Company Information
13.6.2 Takeda Pharmaceutical Company Limited Prostate Cancer PARP Inhibitor Drugs Product Portfolios and Specifications
13.6.3 Takeda Pharmaceutical Company Limited Prostate Cancer PARP Inhibitor Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Takeda Pharmaceutical Company Limited Main Business Overview
13.6.5 Takeda Pharmaceutical Company Limited Latest Developments
13.7 BeiGene, Inc
13.7.1 BeiGene, Inc Company Information
13.7.2 BeiGene, Inc Prostate Cancer PARP Inhibitor Drugs Product Portfolios and Specifications
13.7.3 BeiGene, Inc Prostate Cancer PARP Inhibitor Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 BeiGene, Inc Main Business Overview
13.7.5 BeiGene, Inc Latest Developments
13.8 Jiangsu Hengrui Pharmaceuticals Co., Ltd
13.8.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd Company Information
13.8.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd Prostate Cancer PARP Inhibitor Drugs Product Portfolios and Specifications
13.8.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd Prostate Cancer PARP Inhibitor Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd Main Business Overview
13.8.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd Latest Developments
14 Research Findings and Conclusion